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Antagonistic pleiotropy in mice 
carrying a CAG repeat expansion 
in the range causing Huntington’s 
disease
A. J. Morton, E. A. Skillings, N. I. Wood & Z. Zheng
Antagonist pleiotropy, where a gene exerts a beneficial effect at early stages and a deleterious effect 
later on in an animal’s life, may explain the evolutionary persistence of devastating genetic diseases 
such as Huntington’s disease (HD). To date, however, there is little direct experimental evidence to 
support this theory. Here, we studied a transgenic mouse carrying the HD mutation with a repeat of 50 
CAGs (R6/2_50) that is within the pathological range of repeats causing adult-onset disease in humans. 
R6/2_50 mice develop characteristic HD brain aggregate pathology, with aggregates appearing 
predominantly in the striatum and cortex. However, they show few signs of disease in their lifetime. On 
the contrary, R6/2_50 mice appear to benefit from carrying the mutation. They have extended lifespans 
compared to wildtype (WT) mice, and male mice show enhanced fecundity. Furthermore, R6/2_50 
mice outperform WT mice on the rotarod and show equal or better performance in the two choice 
discrimination task than WT mice. This novel mouse line provides direct experimental evidence that, 
although the HD mutation causes a fatal neurodegenerative disorder, there may be premorbid benefits 
of carrying the mutation.
Huntington’s disease (HD) is a progressive genetic neurodegenerative disorder caused by the unstable expansion 
of a CAG repeat in the HD gene (HTT)1,2. It is characterized by a complex set of symptoms that include motor 
dysfunction, cognitive decline and psychiatric disorder. By end stage of the disease, total brain weight is reduced 
by 10–20%. This is mainly due to degeneration and atrophy of neurons in the caudate nucleus, putamen and 
neocortex. There is an inverse relationship between age-at-onset and CAG repeat length, and patients carrying 
longer alleles typically present as juveniles. In most (>90%) patients, the length of the repeat in the mutant allele 
causing adult-onset disease is 40–50 CAGs. Understanding why HD is an adult onset disorder is a key question 
in the field. It is also not clear why the HD gene mutation persists in the population when it causes such a devas-
tating illness.
Pleiotropy is defined as the production by a single gene of two or more apparently unrelated phenotypic 
effects. Antagonistic pleiotropy is when at least one of these traits is beneficial and at least one is detrimental to 
the fitness of the organism3. The idea that antagonistic pleiotropy plays a role in HD was first suggested by Roger 
Albin in 19884, although HD had been identified as a possible pleiotropic disease many years earlier by Peter 
Medawar5. In his paper, Albin described apocryphal evidence and also reviewed epidemiological data suggesting 
that HD patients are more fecund than non-gene carriers4. There is both direct and indirect evidence to support 
this idea6–8. More recently, the idea of antagonistic pleiotropy in HD re-emerged, with new evidence showing 
that there is a reduced incidence of cancer in HD patients9,10 and that small interfering (si) RNAs based on the 
HD gene are toxic to cancer cells11. If HTT is an example of a gene showing antagonistic pleiotropy, then this 
may explain, at least in part, why HD persists in the population despite its eventual devastating effects on the 
individual.
For a gene to be antagonistically pleiotropic it must be selected for beneficial effects early in life; the ‘unse-
lected’ deleterious effects appear post-reproductively. In HD, both improved reproductive fitness and a reduced 
risk of early onset cancer could be benefits of carrying the mutation. While the mechanisms for improved 
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reproductive fitness are not known, it has been suggested that the reduced cancer risk may be associated with 
increased activity of the tumour suppressor protein p5312. P53 has a role in inducing apoptosis and a higher level 
of p53 may also protect from tumour growth and cancer development in general.
It would help greatly in understanding possible early benefits of the HD mutation if we knew the role played by 
the protein product huntingtin (Htt). Htt interacts with many binding partners and has been implicated in many 
intracellular processes, yet its function remains unknown13. It is clear that Htt is essential in development, since 
deleting both copies of the gene cause early embryonic lethality14. By contrast, Htt does not appear to be essential 
in the adult, since heterozygous knockout mice appear to be normal, as do humans carrying a single copy of the 
gene2. In fact, the role of Htt appears to change with age, since inducible knockout in young mice causes acute 
pancreatitis, but has no deleterious effect in the adult15, and patients with compound heterozygous variants of 
HTT presented with a complex neurodevelopmental disorder that is not HD16. If there is an evolutionary advan-
tage to carrying a mutation in Htt, then better understanding of this early role is essential. For example, knowing 
when a mutation is advantageous may inform us about the timing of disease onset. It is possible that the disease 
starts only when the balance between the deleterious phenotypic effects shifts to outweigh any potential beneficial 
effects of a particular mutation. Not only that, but if there are beneficial effects of the HD gene before the onset of 
disease, this will become an important consideration in deciding when to start treating a patient, particularly with 
gene therapies that involve permanent knock-down of mutant Htt.
HD is one of the few diseases in which antagonistic pleiotropy can be tested experimentally, because of the 
well-characterized mouse models available for study. Numerous HD mice models exist that have been used to 
model every aspect of HD, including brain pathology, behavioral deterioration, CAG repeat instability, gene 
expression changes, circadian rhythm, and sleep abnormalities17,18. Despite their unquestionable value, however, 
one caveat to these studies is that all of these HD mice carry CAG repeat expansions much longer that those seen 
in HD patients. Most carry repeats of 110–250 CAGs, and there are no HD mouse models yet characterised that 
carry a CAG repeat within the typical human range. The shortest repeat length mice shown to cause a behavio-
ral phenotype is 80 CAG repeats in a N171 fragment of HD19 and in a ‘knock-in’ mouse20. This is at the upper 
extreme of somatic CAG repeat length seen in juvenile-onset HD patients. In order to test antagonistic pleiotropic 
effects of the mutation, the CAG repeat length of the mutant allele should be within the range causing disease in 
humans.
In this study, we describe a novel line of R6/2 mice carrying 50 CAG repeats, which is in the range of repeat 
lengths causing adult onset HD. By 3 years of age, this mouse has extensive HD-relevant brain pathology in the 
form of aggregates of mutant Htt. The morphology and distribution of the aggregates is similar to that of aggre-
gate pathology in HD patients, with abundant aggregates in striatum and cortex but few in hippocampus or 
cerebellum. Remarkably, R6/2_50 mice show no deleterious behavioral effects of the mutation. Rather, they seem 
to have improved fitness, with increased fecundity, survival and stamina. These findings are consistent with the 
mutant HD gene exhibiting antagonistic pleiotropy.
Results
Origin of the R6/2_50 CAG repeat line of mice. The CAG repeat in the exon 1 fragment of the Htt gene 
in R6/2 mice is inherently unstable (for references, see2,21). In our colony, CAG repeat instability in the germline 
is an expansion of the order of 1–3 CAGs per generation. Occasionally, however, we see a larger expansion. 
Selectively breeding mice with such expansions has allowed us to establish an allelic series comprising multiple 
lines of R6/2 mice with different CAG repeats lengths between 110 and >450. For our behavioral studies we 
typically breed from mice with 250 CAG repeats. Most R6/2 250 mice in our colony inherited a CAG repeat that 
is similar to (95%) or longer (5%) than their sire (Fig. 1A). Contractions in the germline from 250 CAG are rare. 
In fact, we have only seen 8 contractions larger than 3 CAGs in the 20 years we have been breeding R6/2 mice.
In 2009, we identified a single mouse carrying 50 CAG repeats. This mouse was the offspring of an R6/2 
male mouse carrying 251 CAG repeats and a normal female F1 C57Bl6J/CBA (Fig. 1B). The littermates of this 
mouse, and all other offspring of the sire carried average CAG repeat sizes of 257 ± 1 (N = 15). We bred from this 
mouse to establish a colony of 50 CAG repeat mice. We have now bred this line of mice for >20 generations. The 
mutation is stably transmitted and stable in transmission size. The repeat is pure CAG with no interruptions. 
The transgenic offspring of this male have a mean CAG repeat of 52.4 ± 0.2 (N = 1072). [Note that because the 
founder carried 50 CAG repeats, we call this line R6/2_50].
Greater fecundity in R6/2_50 mice compared to WT mice. In contrast to R6/2 mice with 250 CAG 
repeats (where females are infertile and males have a short reproductive window and are only capable of siring 
pups between 5–8 weeks of age) both male and female R6/2_50 mice are fertile. Female R6/2_50 mice carry pups 
successfully to term, and raise them normally. In fact, they are good mothers, and showed little of the cannibalisa-
tion that is typically seen in naïve WT dams. The reproductive capability of male R6/2_50 mice is also enhanced, 
not only compared to the parent line, but also to WT mice. In WT mice, a decline in breeding is typically seen at 9 
months-1 year of age (unpublished observations (AJM) and Jackson Laboratory Resource Manual; http://jaxmice.
jax.org/manual/breeding_strategies_manual.pdf). By contrast, R6/2_50 mice are capable of breeding for at least 
2 years. Indeed, we have set male breeders up at 2.5 years that have reproduced successfully. The R6/2_50 founder 
mouse bred for ~2 years (98 weeks), siring 16 consecutive litters from 4 sequential WT breeding females. The last 
litter sired by that mouse (that survived to 2.5 years) was born 2 weeks after he died. The litter size remained stable 
(9 ± 1) and the repeat size number passed to offspring did not change significantly over this period (Fig. 1C). We 
studied the enhanced breeding capabilities systematically with 4 other R6/2_50 mice, replacing the normal female 
breeder mouse when they stopped breeding. All 4 R6/2_50 male mice continued breeding beyond 2 years.
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General health in R6/2_50 mice and WT mice. R6/2_50 mice are physically robust. They show normal 
growth and do not lose body condition up to 2 years of age (Fig. 2A,B). Not even the oldest R6/2_50 mice (>3 
years) show the characteristic ‘R6/2 phenotype’ (cachexia, pronounced lordokyphosis, ptosis). Although they 
show signs of aging such as greying fur and mild lordokyphosis, they are active with bright wide-open eyes and 
glossy coats (Fig. 2C).
Glycosuria is observed in R6/2 mice with CAG repeat lengths of 110–25022,23. Aged WT mice also show 
age-related glycosuria. Some, but not all, WT and R6/2_50 mice that survived for 2 years develop glycosuria, but 
there was no difference between the genotypes (Fig. 2D).
Improved survival of R6/2_50 compared to WT mice. R6/2_50 mice can live longer than their WT 
littermates. Soon after we isolated this line, we conducted a small survival study using F2 R6/2_50 mice and 
their age-matched littermates. Group sizes were not matched because at the start of this study we expected the 
R6/2_50 mice (N = 68) to die before the WT mice (N = 15). Unexpectedly, when all of the WT mice had died 
there were still 10 R6/2_50 mice alive. Of the first 50% of mice to die, significantly more WT than R6/2_50 mice 
died (p < 0.001, χ2 11.6, hazard ratio 3.5). Of the second 50% to die, there was a trend for improved survival 
in R6/2_50 mice (p = 0.06, χ2 3.4, hazard ratio 2.0). Of the WT mice, 10/15 and 38/68 R6/2 mice survived for 
2 years. Only 1 WT mouse (6%) and 16 (24%) R6/2 mice survived for more than 2.5 years. The 4 oldest mice 
R6/2_50 mice survived for ~3 years. The 6 oldest WT mice that died naturally over the age of 2 years died signifi-
cantly earlier than the 6 oldest R6/2_50 mice (1023 ± 3 d (~146 w) vs. 1066 ± 12 d (~152 w) respectively, p < 0.01, 
χ2 9.4, hazard ratio 3.6).
Improved survival of Hdh 50 CAG repeat mice compared to WT mice. We studied survival in a full 
length ‘knockin’ line of mice that carries a 50 CAG repeat mutation (Hdh 50; made by Dr Peter Detloff, University 
of Alabama at Birmingham (Suppl. Fig. 1). Hdh 50 mice also showed a significant improvement in survival com-
pared to the WT littermates, with the second half of the Hdh 50 cohort dying significantly later (Log rank test; 
p < 0.05, χ2 5.8, hazard ratio 2.0).
R6/2_50 mice show enhanced motor performance on the rotarod. Up to a year of age, there was 
no difference in performance between WT and R6/2_50 mice on fixed speed rotarod (data not shown). By 72 
weeks, however, performance of R6/2_50 mice was significantly better than that of WT mice (Fig. 3). From then 
on, there was a main effect of genotype that persisted until 104 weeks (at 72 weeks, F(1,1504) = 94.60, p < 0.002; 92 
weeks F(1,1264) = 16.81, p < 0.001; 104 weeks F(1,944) = 13.58, p < 0.001; 124 weeks F(1,144) = 4.27, p < 0.04). By week 
128, all of the WT mice were dead. Week 132 was the last week that surviving 50 CAG repeat mice were tested on 
the rotarod.
Figure 1. Inheritance of CAG repeat lengths in the parent R6/2 mouse line (R6/2_250) and the offspring of the 
CAG_50 line founder mouse. The distribution of CAG repeat lengths in the 250 CAG repeat colony (A) shows 
a tendency for a small expansion (A′) compared with the CAG repeat length of the sire. The CAG repeat lengths 
of all of the TG siblings (triangles in B) of the R6/2_50 founder (arrow in B) were similar to that of the sire. All 
of the TG offspring of the founder mouse (N = 16 litters) carried a CAG repeat of ~52. (C) Triangles in (B and 
C) represent individual mice in separate litters.
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We tested some mice on the accelerating rotarod at two years of age. Not all mice were included, because they 
could not stay on the rotarod for more than 1 minute. Of the mice that stayed on the rotarod for more than 1 min-
ute (5/10 WT and 9/38 R6/2; p = 0.2), the mean time the mice stayed on the rotarod (shown here as distance that 
the mice walked) was similar (4.0 ± 1.0 m (N = 5 WT) vs. 5.6 ± 0.8 m (N = 29 R6/2_50). The range of the distances 
walked by the mice was, however, much greater for R6/2_50 than WT mice. The furthest a WT mouse walked was 
6.1 m; the furthest an R6/2_50 mouse walked was 16.9 m. One quarter (8/29) of R6/2_50 mice walked more than 
8 m (twice the mean distance walked by the WT mice).
Improved reaction time in female and decreased performance in male R6/2_50 mice during 
two-choice discrimination tasks in the touchscreen. We conducted 5 stages of cognitive testing in 
WT and R6/2_50 mice between 8 months and 2 years of age (for ages and statistics see Table 1). No overall 
changes in performance were seen in R6/2_50 mice. Some minor individual differences were seen at specific 
time points. For example, female R6/2_50 mice had a faster reaction time than WT mice during the reversal 
testing in Stage 2 (Fig. 4A; F(1,18) = 4.96, p < 0.05) and acquisition stage of Stage 3 (Fig. 4B; F(1,18) = 6.23, p < 0.05). 
Female R6/2_50 mice also performed better than their WT counterparts during the acquisition testing in Stage 
3 (Fig. 4C, F(1,18) = 5.35, p < 0.05); for other data see Table 1). In the reversal testing of phase 3, male R6/2_50 
mice performance (% correct) was slightly worse in the retention phase of the task than WT mice (Suppl. Fig. 2A; 
F(1,12) = 6.53, p = 0.021), and at 81 and 104 weeks of age male R6/2_50 mice required a greater number of cor-
rection trials or sessions to reach criterion (F(1,13) = 7.04, p < 0.05 and F(1,11) = 5.50, p < 0.05 respectively) and 
were slower to reach criterion in the reversal of Stage 1 testing (Suppl. Fig. 2B). Overall, however, the differences 
between genotypes were subtle, with some aspects of the cognitive phenotypes improving and others worsening, 
but most not being measurably different from normal. The clinical relevance of these differences is not clear, 
although it should be noted that the touchscreen testing protocol was designed to detect deficits, not improve-
ments, in cognitive performance. The group sizes were calculated from previous studies to be sufficiently well 
powered to detect deficits in performance. Ceiling effects mean, however, that the study is likely to be underpow-
ered for detecting improvements in performance.
HD-like pathology in striatum and cortex but not hippocampus of R6/2_50 mice. Progressive 
mutant Htt aggregate pathology (as revealed using MW8 and ubiquitin immunohistochemistry) is seen in the 
brains of R6/2_50 mice. At 1 year of age, occasional small (<2 µm diameter) aggregates of mutant Htt are present 
Figure 2. General health of R6/2_50 transgenic mice is better than WT littermates. Mean (±SEM) body weight 
of male (A) and female (B) mice show the growth and maintenance of body weight R6/2_50 mice (red symbols) 
compared to their WT littermates (black symbols). Since the mean body weight, and variance changed when 
any animals died, the data shown in Fig. 2 are taken from a subgroup of mice within this group that survived for 
2 years. The photograph in (C) shows an R6/2_50 CAG repeat mouse aged 3 years. The characteristic ptosis is 
absent, although the fur is greying. Age-related glycosuria was seen in both WT and R6/2_50 mice (P > 0.05).
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in cortex and striatum of R6/2_50 mice. By 2 years of age, there is an increase in the number of cells containing 
aggregates, in both cortex and striatum. By 2.5 years, cortical and striatal aggregates are abundant, as are aggre-
gates in some nuclei in the thalamus. We had 4 mice survive to 3 years of age. The brain size of all of these mice 
was normal, and their macroscopic morphology was also normal. Nevertheless, there were numerous Htt-positive 
aggregates seen in these brains, particularly in striatum and cortex (Fig. 5 and Suppl. Figs 3–6). Neuropil aggre-
gates were very common, with multiple shapes and forms of immune-positive material that included neuropil 
threads, ‘beads-on-strings’, granular aggregates and diffuse cytoplasmic immunoreactivity. Every form of aggre-
gate that has been identified in HD brain24,25 was seen in the R6/2_50 mouse brain. Although the aggregate den-
sity and morphology varied from mouse to mouse, the pattern of aggregate distribution was similar. Aggregates 
in three of the mice were sparser and smaller than those present in the fourth mouse. In mouse 4, the pathology 
seemed more advanced than that of the other mice, with more numerous and larger aggregates. We have therefore 
used this mouse to illustrate the end stage pathology in this line of mice.
Figure 3. Performance of variable speed rotarod is better in R6/2_50 than WT mice. Rotarod performance is 
shown at 52 (A), 72 (B), 92 (C), 104 (D), 124 (E) and 132 (F) weeks of age in WT (black symbols) and R6/2_50 
(red symbols) mice. At 132 w, only R6/2_50 mice were able to perform on the rotarod. Data points show 
mean ± SEM. *P < 0.04, **P < 0.002, ***P < 0.001.
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In mouse 4, MW8-positive aggregates were found primarily in the striatum (Fig. 5A,C and Suppl. Fig. 3) and 
cortex (Fig. 5B and Suppl. Figs 4–6). Aggregates were also found in the thalamus, substantia nigra and molecular 
layer of the cerebellum (data not shown), but none were found in principal neurons of the hippocampus (Suppl. 
Fig. 7). Aggregates varied in size and shape, and displayed all of the morphologies described for aggregates in HD 
brain24,25 (Fig. 5 and Suppl. Figs 3–6). These included the characteristic neuronal nuclear inclusions (NIIs) as well 
as perinuclear and neuritic aggregates typically seen in HD mice26. Neurons in the dorso-lateral striatum showed 
a higher density of NIIs than any other part of the brain. In cortex, NIIs were found predominantly in neuronal 
nuclei in layer 5/6 but also occasionally in layer 2. Extranuclear aggregates were found in all cortical layers, with 
many small inclusions in linear format, consistent with their presence in neurites. In the hippocampus, there were 
no aggregates seen in principle neurons of Cornu Ammonis (CA), or in the dentate gyrus (Suppl. Fig. 7). This is 
in marked contrast to the pathology typically seen in mouse models with longer CAG repeats, where aggregates 
appear first in CA126,27 and are eventually found in all classes of hippocampal neurons, including granule neurons 
of the dentate gyrus. Interestingly, as seen in HD patients24, significant Htt immunoreactivity was seen in white 
matter, with aggregates present in corpus callosum, fibre bundles in the striatum, and white matter in the cere-
bellum (Suppl. Fig. 8).
Discussion
We describe a novel line of HD mice carrying a mutation with a 50 CAG repeat expansion that is in the range 
causing adult–onset HD. This line of mice has two striking and unusual features. First, the post mortem aggregate 
pathology is more similar to the pattern seen in HD than of any line of mice reported hitherto, with aggregates 
appearing predominantly in the striatum and cortex, but not in hippocampus or cerebellum. Although some 
mice, e.g. the Q140 knockin28, and the Hdh 150 knockin mouse29, show first presentation of inclusions pre-
dominantly in the striatum, both of these lines eventually develop aggregates in all brain regions, including hip-
pocampus28 and cerebellum (unpublished observations, AJM). Second, despite the eventual widespread HD-like 
pathology, R6/2_50 mice do not show pronounced behavioral abnormalities. On the contrary, they appear to 
benefit from carrying the mutation, since they are more robust than their WT littermates (as judged by their 
superior performance in locomotor tasks, reproductive fitness, and survival). A second line of HD mice with a 
CAG repeat mutation of 50 carried as a ‘knockin’ also shows improved survival compared to WT mice. Together 
these data support the idea that the mutant HD allele shows antagonistic pleiotropy, with beneficial effects on 
multiple domains in adult mice, despite the eventual development of HD-like brain pathology that is the harbin-
ger of full-blown disease.
The R6/2_50 line of mice shows the desired regional specificity of CAG-related pathology that has been so 
lacking in HD mouse models to date. Thus, it appears that differential regional distribution of aggregates depends 
more on the length of the CAG repeat expansion than its genetic context, since R6/2_50 mice carry the CAG 
repeat expansion in only a fragment of HTT. This should resolve one of the concerns of the field about HD models 
in general, and R6/2 lines in particular. The aggregate brain pathology in R6/2 mice with repeat lengths between 
110–250 does not start in the striatum or cortex, the regions that degenerate in HD2. Rather, aggregates appear 










Number of sessions to reach 
criterion
sex M F M F M F M F M F
Stage 1
Acquisition 1 8 p = 0.202 p = 0.119 p = 0.095 p = 0.451 p = 0.253 p = 0.593 p = 0.279 p = 0.146 p = 0.566 p = 0.230
Reversal 1 11 p = 0.137 p = 0.149 p < 0.05R6/2 slower p = 0.464 p = 0.248 p = 0.711 p = 0.141 p = 0.445 p = 0.138 p = 0.174
Retention 1 20 p = 0.450 p = 0.136 p = 0.171 p = 0.154 p = 0.931 p = 0.393 p = 0.398 p = 0.523 p = 0.144 p < 0.05R6/2 better
Stage 2
Acquisition 2 21 p = 0.228 p = 0.452 p = 0.606 p = 0.394 p = 0.629 p = 0.372 p = 0.813 p = 0.422 p = 0.279 p = 0.966
Reversal 2 24 p = 0.201 p = 0.574 p = 0.457 p = 0.154 p = 0.423 p < 0.05R6/2 faster p = 0.287 p = 0.436 p = 0.876 p = 0.413
Stage 3
Acquisition 3 36 p = 0.572 p < 0.05R6/2 better p = 0.286 p = 0.051 p = 0.286
p < 0.05
R6/2 faster p = 0.100 p = 0.850 p = 0.338 p = 0.077
Reversal 3 41 p = 0.484 p = 0.176 p = 0.286 p = 0.064 p = 0.244 p = 0.156 p = 0.356 p = 0.604 p = 0.350 p = 0.230
Retention 2 64 p < 0.05R6/2 worse p = 0.322 p = 0.307 p = 0.445 p = 0.931 p = 0.393 p- = 0.337 p = 0.523 p = 0.304 p = 0.573
Stage 4
Acquisition 4 81 p = 0.073 p = 0.258 p = 0.083 p = 0.705 p = 0.574 p = 0.199 p < 0.05R6/2 worse p = 0.124 p = 0.312 p- = 0.563
Stage 5
Acquisition 5 104 p = 0.068 p = 0.230 p = 0.281 p = 0.712 p = 0.544 p = 0.678 p = 0.069 p = 0.293 p < 0.05R6/2 worse p = 0.293
Table 1. Summary of statistical analyses of touchscreen data.
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widespread pathology, along with misgivings about the rapid onset of disease in R6/2 mice, triggered a debate 
focused on the appropriateness of fragment models that has continued for many years, despite prima facie evi-
dence that fragment models recapitulate many of the genetic changes seen in HD30, and that mice carrying the 
HD mutation in a more ‘relevant’ genetic context (e.g. full length knockin Hdh Q150, and BAC HD lines) show 
a widespread pattern of aggregate brain pathology29,31. The restricted HD-like cortico-striatal histopathology in 
the R6/2_50 mice suggests that the widespread pathology in most HD models is related to the exaggerated CAG 
repeat size, rather than the nature of the transgene (knockin vs. fragment). Notably, the HD-relevant pathology 
of the R/2_50 mouse offers a unique opportunity to study the regional specificity of early brain pathology in HD, 
an understanding of which has been particularly elusive.
Whilst there are at least two other mouse models that carry short repeats (~50CAG), a full length cDNA trans-
genic mouse32 and a knockin mouse33, the transgenic mouse line had extensive aggregate pathology in multiple 
regions, including cortex, striatum and hippocampus and the mice died at around 25 weeks32. The knockin mouse 
showed appeared normal up to 6 months, but was not characterised past that age. Two lines of transgenic (tg) HD 
Figure 4. Reaction time and performance of female R6/2_50 mice during cognitive testing in the touchscreen. 
Data show the mean reaction times (as the time taken to respond to the first presentation of a stimulus pair) 
during acquisition and reversal during testing Phase 2 (A) and 3 (B), and performance (percentage of correct 
choices made) at acquisition and reversal during testing Phase 3 (C). Data points show mean ± SEM. For all 
panels, filled circles (·) represent WT mice and open circles (o) represent R6/2 mice. Dotted lines indicate 
chance (50%) and criterion (70%) levels. *p < 0.05.
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rat have also been generated, that carry a CAG repeat of 51 (SPRDTgHD34 and F344tgHD35). Both HD rat lines 
show Htt-positive aggregate pathology by 21 months, particularly those regions associated with regulation of 
emotion (nucleus accumbens, amygdala), although up to 21 months neither strain show strong cortical staining 
and both show significant hippocampal staining34,35. Clearly, differences in transgene construct, promoter and 
expression levels and species differences, as well as different antibodies used for visualisation of brain pathology 
make direct comparisons of these lines of HD rodent models with the R6/2_50 mouse inadvisable. As with the 
R6/2_50 mice, the tgHD rat cognitive phenotype evolution is complex, with both improved and worsening phe-
notypes being measurable compared to WT rats. It is nevertheless intriguing to note that at an early age, both 
lines of tgHD rats are more social and less anxious than WT rats35,36 and the performance of young SPRDTgHD 
rats on the rotarod is better than that of the WT controls36. SPRDTgHD rats also showed better learning and 
reacquisition of discriminative fear conditioning37.
We show direct evidence that antagonistic pleiotropy may play a role in the phenotypic development of the 
R6/2_50 repeat mice. A retrospective review of the literature reveals, however, that there are numerous examples 
of potentially beneficial effects of the CAG repeat mutation in HD mouse models, even in lines that have rapid 
disease onset. Most notable are studies whereby HD mice are shown to be resistant to the effect of exogenous neu-
rotoxins. For example, despite the rapidly progressing deleterious phenotype seen in mice carrying repeat lengths 
of 140–250 CAGs, R6/2 mice are resistant to the effects of several neurotoxins including quinolinic acid38,39, 
kainic acid40, 3-nitropropionic acid41, N-methyl-d-aspartate (NMDA) and malonate42,43 as well as to ischaemic 
insult44. Mice from a related line (R6/1) are resistant to global cerebral ischaemia45, and N-171-82Q mice46 and 
YAC mice carrying 140 CAGs47,48 show resistance to excitotoxicity caused by NMDA and/or quinolinic acid. 
FVB/N mice, which are highly vulnerable to excitotoxicity, also become resistant to quinolinic acid-induced stri-
atal neurodegeneration with age, when carrying a full length Htt transgene carrying a CAG repeat 14048. Finally, 
R6/2 mice show reduced sensitivity to neurotoxicity induced by dopamine and 6-hydroxy dopamine49. Although 
the mechanisms underlying resistance to exogenous insults remain elusive, they appear to be independent of 
short-term expression of endogenous neuroprotective proteins39,45. A number of groups have tried to link the 
endogenous neuroprotection in HD mice with particular pathways, e.g. p5350–52, but to date, no clear mechanism 
has emerged. Nevertheless, together these studies show that the presence of a pathological length CAG repeat 
results in a dramatic resistance to damaging, and in some cases lethal, excitotoxic insults.
As well as resistance to excitotoxins, there are other mutation-related changes in HD mice that might be 
beneficial. Although body weight loss is a complex marker, both YAC mice and BAC HD mice are heavier than 
WT mice53,54, suggesting that the third copy of the HTT gene is beneficial. A heavier body weight is correlated, 
not only with better survival and delayed onset of disease in HD mice55,56 but also with a slower progression of 
disease in HD patients57,58. While it is not clear if deliberately maintaining a good body weight in HD patients 
Figure 5. Aggregate pathology is prominent in striatum and cortex in R6/2_50 mice. The photomicrographs 
show immunoreactivity for aggregated Htt (MW8) in the striatum (A,C) and ubiquitin in the cortex (B). 
The cartoon indicates the location of the striatal and cortical sections from coronal sections of brain. The 
white arrowheads indicate examples of classic nuclear inclusions; the black arrows indicate examples of large 
extranuclear aggregates; the black arrowheads indicate ubiquitin-positive material in neuritic processes. The 
bars in A = 200 µm for (A,B) and 20 µm for (C). For other histology, see Suppl. Figs 1–7.
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can slow the disease, there is no doubt that body weight loss in HD patients typically heralds the beginning of the 
end-stage of HD. Interestingly, behavioural testing shows that BACHD mice exhibited higher efficiency of reward 
collection than WT animals, a characteristic that became more pronounced with age59. Consistent with this, there 
is some evidence that premanifest HD gene mutation carriers show enhanced perceptual learning60. Finally, early 
behavioural data from our lab show that R6/2 mice (with repeats of ~140) have superior cognitive performance to 
that of WT mice at presymptomatic ages (see Fig. 5B,C in ref.61). This is interesting, since this line of mice with a 
CAG repeat of ~140 had a rapidly accelerating phenotype, and at 8 weeks, their reproductive capacity was already 
severely compromised. Thus, the beneficial effects of the transgene on cognition were dissociated from the repro-
ductive capabilities of these mice.
The core tenet of the antagonistic pleiotropy theory is that the forces of natural selection weaken with age and 
that the selective value of a gene depends on how it affects the total reproductive capacity. If a fatal disease such 
as HD happens late in life, its consequences will be completely unimportant to the survival of the population. 
Indeed, it was only in the 19th century that life expectancy at birth outstripped the age-at-onset of HD. It is nota-
ble that not only does HD persist in the population, but it may also increase in frequency. This was predicted by 
both Shokeir and colleagues62 and Rubinsztein et al.63. In fact, there has been an increase in the prevalence in HD 
recorded in the UK64,65, although it remains to be seen if this is due to genetic factors, or to improved methods of 
collecting epidemiological data.
Variation in the CAG repeat length within HTT seems to exhibit a form of antagonistic pleiotropy that 
perfectly illustrates that proposed by Medawar. Unfortunately, HD allele carriers do not enjoy better health. 
Furthermore, although there is some evidence that there is reduced cancer in HD, this is not a hard-and-fast 
rule, since it appears to depend on the type of cancer involved66. Most recently, there is evidence that CAG/CUG 
repeats may be toxic to cancer cells11. This raises the intriguing possibility that CAG repeats are part of a natu-
ral defence mechanism against tumours. We did not systematically investigate tumour formation in our mice, 
although it would clearly be interesting to do so in a future study.
For many years, there has been an interesting debate about the mechanism(s) underlying the persistence 
and prevalence of the expanded CAG repeat that causes HD67–72, and not all of the proposed models require the 
expanded CAG repeat to be subjected to negative selection. In 2011, however, Carter and Nuygen reviewed the 
idea that antagonistic pleiotropy is a feature of human genetic diseases, including HD73. They argued that rather 
than being the ‘exception to the rule’, antagonistic pleiotropy might be a fundamental mechanism for the survival 
of these non-optimal alleles. Most of the diseases Carter and Nuygen considered are recessive human genetic dis-
eases, with heterozygous carriers being protected against (usually) infectious diseases, citing well known evidence 
showing that heterozygote carriers for sickle cell anaemia and beta-thalassemia are protected against malaria, and 
that carriers of the mutation for cystic fibrosis have more offspring and may experience increased resistance to 
cholera and other infectious diseases. They also cite evidence that Tay Sachs disease, a severe neurodegenerative 
disease caused by a number of different mutations in the HEXA gene, may owe its surprisingly high frequency 
to benefits provided by protection from tuberculosis during the historical process of urbanization72–74. HD was 
used as the prime example of a neurodegenerative disease that might exhibit antagonistic pleiotropy, based on the 
increased fertility and decreased risk of cancer. It would be interesting if the HD mutation also protects against 
infection.
The dynamic nature of the mutant Htt-mediated phenotype means that therapeutic approaches to HD may 
need to be ‘personalized’ according to the stage and development of the disease. For example, one promising 
proposed method for treating HD is by silencing gene expression75–77. Treatments that significantly silence the 
expression of an antagonistically pleiotropic allele, however, may lead to a reduction not only in deleterious but 
also in any beneficial effects. By eliminating a problem, we may also eliminate a benefit, such as endogenous pro-
tection against excitotoxicity or tumorigenesis. A better option, if it could be developed, would be to target the 
expanded CAG repeat itself, rather than the whole gene. In the meantime, we suggest that particular attention 
needs to be paid to timing and duration of genetically-based treatment of diseases caused by genes that may show 
antagonistic pleiotropy. Understanding more about the beneficial effects of pleiotropic genes that cause late-onset 
neurodegenerative disease should be part of the critical pathway towards developing future therapies.
Materials and Methods
Mice. This research was regulated under the Animals (Scientific Procedures) Act 1986 Amendment 
Regulations 2012, and following ethical review by the University of Cambridge Animal Welfare and Ethical 
Review Body. Mice were taken from a colony of R6/2 mice established in the University of Cambridge, and main-
tained by backcrossing onto CBA × C57BL6 F1 female mice. Details of the origins of the R6/2_50 CAG repeat 
mice are reported in the Results.
Genotyping methods and detailed husbandry have been described previously78. Briefly, mice were housed in 
single-sex, mixed genotype groups. Water and food were provided ad libitum except for mice undergoing cog-
nitive testing that were placed on a restricted diet for the duration of touchscreen testing periods, such that their 
body weight did not fall below 85% of their free-feeding weight. Genotyping and CAG repeat length measure-
ments were carried out by Laragen (Los Angeles, CA, USA) and reported as determined by GeneMapper.
Survival was assessed in an early generation of R6/2_50 mice (N = 15 WT and 68 R6/2_50). Death was 
recorded if mice were either found dead or if they were killed at the humane end point (failure to exhibit a right-
ing reflex or to rouse after gentle stimulation).
Separate cohorts of mice were used for behavioural testing. N = 47 WT and 113 R6/2_50) were trained and 
tested on the rotarod (Ugo Basile, Varese, Italy). Body weight was measured in another group of aged-matched 
littermates from the same generation (N = 94 WT and 120 R6/2_50) that did not undergo rotarod or any other 
behavioral testing. All mice were weighed twice weekly. Four cohorts of 10 mice of each sex and genotype from a 
later generation were used for cognitive testing (40 mice in total).
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Glycosurea was measured randomly in some mice from all groups using Diastix (Bayer, Basel, Switzerland).
Behavioural testing. Rotarod. For rotarod testing, each mouse received 2 training trials of 60 s per day for 
4 days at a fixed speed of 24 rpm. For the testing, each mouse was given 2 successive trials at each of 7 different 
speeds (5, 8, 15, 20, 24, 31, 33 and 40 rpm) for one minute. At each speed, the latency to fall from the rotarod was 
recorded. The average of both trials at each speed was used for the analysis. In addition, some of these mice were 
tested once on the accelerating rotarod at 2 years (N = 5 WT and 29 R6/2_50). The rotarod was accelerated from 
4–40 rpm over a 10 minute period and latency to fall was recorded. The mean time from three trials (conducted 
on the same day with an inter-trial interval of 2 hours) was used to calculate distance walked.
Two-choice discrimination in the touchscreen. The testing apparatus consisted of operant testing chambers with 
touchscreens as previously described79. Following initial training, there were 5 separate stages of testing (Table 1), 
using two different pairs of brightness-matched stimuli. A correct choice elicited a food reward (14 mg 5 TUL 
purified rodent pellets; TestDiet, MO, USA), while an incorrect choice resulted in a ‘time-out’, whereby the house 
light was extinguished for a period of five seconds. This was followed by a correction procedure, where the mouse 
was required to repeat the trial until a correct choice was made. All mice completed all stages of testing.
At Stage 1, mice were tested from 8 weeks of age on the acquisition of a two choice discrimination (Marbles 
S+: Fan S−). After 14 sessions of acquisition testing the stimuli were reversed (Fan S+: Marbles S−). Mice were 
then tested for a further 24 sessions using the new stimulus-reward contingency (Fan S+: Marbles S−). After a 
5 week break from testing, retention was tested over 7 sessions. At Stage 2, mice (now aged 21 weeks) were pre-
sented with a new stimulus pair (Wing S+; Nut S−). They were tested for 18 sessions of acquisition learning, after 
which the stimuli were reversed. Mice were then tested on the reversal phase of the task for 50 sessions. At Stage 
3, mice (now aged 36 weeks) were started on a new phase of testing using the original stimulus pair (Marbles S+/
Fan S−). They were presented with 25 sessions of acquisition testing followed by a further 24 sessions of reversal 
testing. Following a 20 week break from testing, the mice were tested on the retention of the reversal S+ (Fan) for 
7 days. At Stage 4, the mice (now aged 81 weeks) were retested on the stimulus pair - Marbles S+/Fan S− for 14 
sessions. At Stage 5, the mice (now aged 2 years), were tested for a final time using Marbles S+/Fan S−.
Each of the stages of testing was analysed in terms of performance (percentage correct), reaction time (time 
taken for the mouse to respond to the initial presentation of the stimulus), number of correction trials required to 
complete a session, and mean number of sessions required to reach criterion.
Immunocytochemistry. The antibody staining procedure was performed essentially as previously 
described27, using cryosections (30 µm) of fresh frozen brain tissue. Antibodies used were a rabbit polyclonal 
anti-poly-ubiquitin (1: 2000; Dako, Denmark) and MW8, a mouse monoclonal antibody that recognises 
the aggregated conformation of mutant Htt (1: 2000; kind gift of the late Paul Patterson, Caltech, CA, USA). 
Secondary antibodies were horseradish peroxidase (HRP)-conjugated IgG (1: 2000; Vector, Peterborough, UK). 
Immunoreactivity was visualized using diaminobenzidine (Sigma, Poole, UK). Note that we describe the proteins 
visualized by MW8 as aggregated ‘mutant Htt’. This is not strictly accurate, since the transgene contains only the 
first exon of the HD gene. Thus, the major protein species found in inclusions is not full length Htt, but rather is a 
mutant fragment of Htt with a pathological length polyglutamine repeat.
Statistical analysis. Statistical analyses were performed using Statsoft Statistica v13 software (Statsoft, 
Tulsa, Oklahoma, USA). Unless otherwise stated, data from male and female mice were analysed separately, using 
repeated-measures analysis of variance (ANOVA), with genotype as a factor. Bonferroni’s post-hoc tests were 
performed when significant group effects were identified. Survival comparison was tested with the Log rank test. 
Significance levels were set at p < 0.05.
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